CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Vor Bio, Korro Bio, Insitro and Rallybio revealed plans to lay off chunks of their respective workforces in the latest job ...

The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

The startup’s first prospect is a heart medicine that works differently than the hypertrophic cardiomyopathy drugs developed ...

While updated study results confirmed the drug lowers a target protein, the therapy's effect on clinical outcomes was less ...

Experts say market turmoil has made it harder for buyers and sellers to agree on price, which can be an especially imposing ...

Already facing headwinds caused by a patient’s death and treatment delays, the biotech now may have to contend with a less ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

The advisory committee meeting is an important step in the process of readying boosters for the fall and winter season, but ...

A vocal opponent of his predecessor Peter Marks, Vinay Prasad will now lead the office tasked with reviewing some genetic ...